Navigation Links
TetraLogic Pharmaceuticals Announces New Executives
Date:8/19/2013

MALVERN, Pa., Aug. 19, 2013 /PRNewswire/ -- TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule SMAC mimetic drugs to treat cancer, today announced the appointment of a new senior executive leadership team with the goal of accelerating the development of the company and its lead product candidate birinapant. The new TetraLogic senior executives are J. Kevin Buchi, President and Chief Executive Officer, Pete A. Meyers, Chief Financial Officer, and Lesley Russell, MBChB, MRCP, Chief Operating Officer.  John M. Gill, the departing President, Chief Executive Officer and Co-founder of TetraLogic, will continue to serve on the company's Board of Directors.

"I am pleased to hand over the reins to Kevin who is a highly regarded leader within our industry," stated Mr. Gill. "Together with Pete Meyers and Lesley Russell, this team represents the ideal complement to the existing team at TetraLogic, bringing the expertise and experience we need to maximize the value of our lead SMAC mimetic drug candidate birinapant, grow the company, and realize the full economic potential of our commercial opportunities for our shareholders."

"I am honored to be chosen to lead TetraLogic at this very exciting time for the company," stated Mr. Buchi. "With a strong team and clear leadership position in SMAC mimetics, we have a tremendous opportunity to continue the momentum established for birinapant as a potential treatment for both solid tumors and hematological malignancies. Having spent most of my career in the biotech industry, I have a strong sense of the opportunities for success at TetraLogic and look forward to leading the company into what promises to be an exciting future."

Mr. Buchi was most recently Corporate Vice President, Global Branded Products, at Teva Pharmaceutical Industries Ltd. Prior to joining Teva, he was Chief Executive Officer of Cephalon, Inc., which was acquired by Teva for $8 billion in October 2011. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Financial Officer and Chief Operating Officer, before becoming Cephalon's Chief Executive Officer in December 2010.  He graduated from Cornell University with a Bachelor of Arts degree in chemistry and received a Master of Management degree from the J.L. Kellogg Graduate School of Management at Northwestern University.  Mr. Buchi is a Certified Public Accountant.

Mr. Meyers was most recently Managing Director, Co-Head of Global Health Care Investment Banking at Deutsche Bank Securities Inc.  He joined Deutsche Bank in 2005 after serving six years with Credit Suisse First Boston LLC where he was a Managing Director in Health Care Investment Banking specializing in the biotechnology and pharmaceutical sectors.  Prior to that, he worked at Dillon, Read & Co., specializing in health care mergers and acquisitions.  Mr. Meyers earned a Bachelor of Science degree in finance from Boston College and a Master of Business Administration degree from Columbia Business School.

Dr. Russell is a hematologist/oncologist with more than 20 years of international pharmaceutical industry experience and leadership in the therapeutic areas of hematology/oncology, neurology, psychiatry, pain and inflammation, respiratory medicine, cardiovascular medicine and stem cell therapy. Dr. Russell was most recently Senior Vice President and Global Head, Research and Development, Global Branded Products for Teva Pharmaceuticals USA. She was appointed to this role upon Teva's acquisition of Cephalon, Inc., where she served as Executive Vice President and Chief Medical Officer from 2006 to 2011. She joined Cephalon in 2000 as Vice President, Worldwide Clinical Research. Prior to Cephalon, she served as Vice President, Clinical Research at US Bioscience Inc. and held positions of increasing responsibility within the company from 1996 to 1999. From 1995 to 1996, she was a clinical research physician at Eli Lilly U.K. and a medical director at Amgen U.K. from 1992 to 1995. Dr. Russell was trained in hematology/oncology at Royal Infirmary of Edinburgh and at Royal Hospital for Sick Children, Edinburgh. She received an MBChB from the University of Edinburgh, Scotland, is a member of the Royal College of Physicians, United Kingdom and is registered with the General Medical Council, United Kingdom.

About Birinapant
Birinapant (formerly TL32711) is a small molecule peptidomimetic of SMAC (second mitochondrial-derived activator of caspases), an endogenous regulator of apoptotic cell death, that antagonizes the inhibitor of apoptosis proteins (IAPs). Birinapant is in clinical development for the treatment of solid tumors and hematological malignancies. In clinical studies to date, birinapant has been well-tolerated and exhibited suppression of IAPs and antitumor activity.

About TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that focuses on the discovery and development of second mitochondrial-derived activator of caspases (SMAC) mimetics, small molecule drugs that mimic SMAC  for the treatment of cancers. The company's institutional investors include Clarus Ventures, HealthCare Ventures, Quaker Partners, Novitas Capital, Nextech Invest Ltd, Hatteras Venture Partners, Pfizer Ventures, Latterell Venture Partners, the Vertical Group, Amgen Ventures, and Kammerer Associates.  For additional information, please refer to the company's Web site at www.tetralogicpharma.com.


'/>"/>
SOURCE TetraLogic Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 In response to the ... FDA,s Deputy Commissioner for Medical Products and Tobacco, along with ... reassess the agency,s approach to opioid medications. The plan will ... providing patients in pain access to effective relief. ... , Re-examine the risk-benefit paradigm for opioids and ...
(Date:2/4/2016)...  Blueprint Medicines Corporation (NASDAQ: BPMC ), ... investigational kinase medicines for patients with genomically defined ... of directors of Lonnel Coats , a ... industry-related experience. Jeffrey Albers , ... strategic experience developing and commercializing numerous oncology products ...
(Date:2/4/2016)... SIOUX FALLS, S.D. , Feb. 4, 2016 ... patient and guest technology solutions, today announced that ... SONIFI Health Senior Living Engagement System. The system ... information tool that residents access through a tablet ... --> The resident engagement system provides access ...
Breaking Medicine Technology:
(Date:2/7/2016)... Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February 07, 2016 , ... ... Friday in recognition of National Wear Red Day. National Wear Red Day is ... and stroke in women. Heart disease and stroke cause 1 in 3 deaths among ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... ADVISORY: 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , ... the world with an estimated 5000 perioperative nurses in attendance to study ...
(Date:2/6/2016)... ... February 06, 2016 , ... Shark Finds and Kevin ... of a new DRTV campaign with Belly Bands. , Having a dog is great—except ... to puppy pads and find nothing works, get Belly Bands, the easiest way ...
(Date:2/5/2016)... ... 05, 2016 , ... Love is in the air at King Kullen! The ... and packaging. This staple for Valentine’s Day is a must-have, and can be picked ... Day, not only are long-stem roses available, but also other flower bouquets, elegantly wrapped ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... setting the stage for new clinical and scientific initiatives have all marked the ... she was appointed President and CEO of the nation’s oldest cancer center, Candace ...
Breaking Medicine News(10 mins):